Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Friday, February 01, 2013
Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced plans for additional investment in its Milton Park facility. Located in Oxfordshire, UK, Milton ...
read more
Particle Sciences, Inc. has expanded its development
capabilities to accommodate the increasing demand for biopharmaceutical formulation and
analysis. According to Robert Becker, Vice President Biopharmaceutical Sales and Business
Development ...
read more
Wednesday, November 06, 2013
The strategies and timing of outsourcing pharmaceutical development processes to a contract testing laboratory will be the focus of a mini-workshop at the 2013 AAPS Annual Meeting and Exposition on Nov. 12, 2013.
read more
Thursday, February 09, 2012
Almac is pleased to announce the doubling of analytical capacity at its 240,000 sq. ft. North American Headquarters. The facility, built on a 40 acre site in Souderton, PA, north of Philadelphia, and occupied since 2010, delivers full-service, ...
read more
Octapharma and BioMatrix Specialty Pharmacy are supporting a new study focused on treating patients with COVID-19 and presenting with COVID-19-associated myocardial dysfunction.
read more
Novozymes Biopharma has entered a new collaborative research agreement with one of the world’s top vaccine companies. The partnership will enable the company to evaluate Novozymes Biopharma's modified recombinant human albumin (rAlbumin) Veltis ...
read more
Thursday, January 17, 2013
Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry today announced that Kristin Arnold, Ph.D. has joined the company as vice president, product development ...
read more
Wednesday, April 11, 2012
As more and more R&D is outsourced by pharmaceutical companies, a study released today provides new insight into how to structure the relevant partnerships for success.
read more
RSSL is to launch several new services to the biopharmaceutical sector, covering all aspects of the EMA regulatory guidelines for safety, quality and efficacy of biopharmaceuticals. Services will be GMP compliant where appropriate.
read more
Friday, December 13, 2013
Thomas Feinberg, PhD, Catalent Pharma Solutions’ Director of Development and Analytical Solutions, is to present at the forthcoming “Suitability and Compatibility for Packaging and Delivery Systems
read more
MPI Research, the largest single-site preclinical/early clinical contract research organization (CRO) globally, is pleased to announce a strategic partnership with inviCRO and 3D Imaging to unite world-class molecular imaging, radiochemistry, and ...
read more
Metrics Inc. has named Dr. Thomas B. “Brad” Gold vice president of pharmaceutical development.
The promotion expands Gold’s previous role as senior director of pharmaceutical development and new technology. Capabilities Gold will manage in his new ...
read more
Metrics Inc. is making significant investments in its facilities and equipment for the benefit of contract services clients by opening a new laboratory to better support fast-track development of pharmaceutical products.
read more
Thursday, February 07, 2013
Metrics Inc. has appointed Joseph E. “Joe” Cobb Jr., CPIP, as director of pharmaceutical development.
read more
Wednesday, March 27, 2013
Medicyte has signed a licensing agreement for the rights to use Lentiviral vector technology from Life Technologies to develop and market next generation, cell-based upcyte® cell products to the biopharma and academic research markets.
read more